

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

**(1) PROPOSED CANCELLATION OF REPURCHASED SHARES AND
PROPOSED REDUCTION OF THE REGISTERED CAPITAL
OF THE COMPANY;
AND**

(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcements of Hangzhou Tigermmed Consulting Co., Ltd. (the “**Company**”) dated February 6, 2024, April 12, 2024, April 30, 2024 and May 29, 2025 (the “**Announcements**”), and the circular of the Company dated April 10, 2024 (the “**Circular**”) in relation to, amongst others, the repurchase of A Shares through centralized price bidding by the Company (“**2024 A Share Repurchase Plan**”). Unless the context requires otherwise, capitalised terms used herein shall have same meanings as those defined in the Announcements and the Circular.

**(1) PROPOSED CANCELLATION OF REPURCHASED SHARES AND PROPOSED
REDUCTION OF THE REGISTERED CAPITAL OF THE COMPANY**

As provided in the Announcements and Circular, according to the 2024 A Share Repurchase Plan, the A Shares purchased pursuant to the 2024 A Share Repurchase Plan shall be used as the Company’s source of shares for subsequent A share equity incentive scheme or A share employee stock ownership plan, and for the reduction of registered capital of the Company. Among others, the number of shares to be used for the implementation of the equity incentive scheme or employee stock ownership plan shall not be higher than 60% of the total number of repurchased Shares, and the number of shares to be used for the purpose of cancellation and reduction of the registered capital shall not be lower than 40% of the total number of repurchased Shares. The Company repurchased an aggregate of 9,806,300 A Shares pursuant to the 2024 A Share Repurchase Plan, which were held as treasury shares of the Company (“**Treasury**

Shares”). On May 29, 2026, the Company cancelled 3,922,520 Treasury Shares, representing 40% of the Shares repurchased under the A Share Repurchase Plan, and reduced the registered capital of the Company from RMB864,948,570 (divided into 864,948,570 Shares) to RMB861,026,050 (divided into 861,026,050 Shares). After the aforesaid cancellation, the number of Treasury Shares which were repurchased pursuant to the 2024 A Share Repurchase Plan and held by the Company were 5,883,780 A Shares.

The Board hereby announces that in light of the Company’s actual circumstances and with a view of safeguarding investors’ interests and bolstering market confidence, on August 28, 2026, at the second meeting of the sixth session of the Board, the Board resolved and approved to change the intended use of remaining 5,883,780 Treasury Shares repurchased pursuant to the 2024 A Share Repurchase Plan originally intended for “subsequent implementation of equity incentive plans or employee stock ownership plans” to “cancellation to reduce registered capital”. Such Treasury Shares repurchased shall be cancelled, and the registered capital of the Company shall be reduced accordingly. Upon completion of the aforesaid cancellation and reduction of registered capital, the total number of the Shares will change from RMB861,026,050 (divided into 861,026,050 Shares) to RMB855,142,270 (divided into 855,142,270 Shares) (“**Proposed Cancellation of Treasury Shares and Reduction in Registered Capital**”).

The table below sets out changes to the shareholding structure of the Company before and after the Proposed Cancellation of Treasury Shares and Reduction in Registered Capital:

Nature of Shares	Before the change		Change (Share)	After the change	
	Quantity (Share)	Percentage (%)		Quantity (Share)	Percentage (%)
I. Circulating Shares subject to selling restrictions	171,426,344	19.91	0	171,426,344	20.05
Locked Shares held by senior management	171,426,344	19.91	0	171,426,344	20.05
II. Circulating Shares not subject to selling restrictions	689,599,706	80.09	-5,883,780	683,715,926	79.95
RMB ordinary Shares (A Shares)	566,474,906	65.79	-5,883,780	560,591,126	65.55
Overseas-listed foreign Shares (H Shares)	123,124,800	14.30	0	123,124,800	14.40
III. Total number of Shares	861,026,050	100	-5,883,780	855,142,270	100

The Directors are of the view that the Proposed Cancellation of Treasury Shares and Reduction in Registered Capital is in compliance with Rules for Share Repurchase by Listed Companies and the Self-regulatory Guidelines for the Companies Listed on the Shenzhen Stock Exchange No. 9 – Repurchase of Shares and other relevant laws and regulations, and will not have material impact on the Company’s financial and operational situation, nor jeopardize the interests of the Company or its minority investors. After implementing the Proposed Cancellation of Treasury Shares and Reduction in Registered Capital, the shareholding structure of the Company will still be able to fulfill the listing conditions of the Stock Exchange and will not affect the Company’s status as a listed company.

The Proposed Cancellation of Treasury Shares and Reduction in Registered Capital is subject to the consideration and approval by special resolution by the Shareholders at the 2026 third extraordinary general meeting of the Company (the “**EGM**”), the 2026 third A Share class meeting of the Company (the “**A Share Class Meeting**”) and the 2026 third H Share class meeting of the Company (together with the A Share Class Meeting, collectively, the “**Class Meetings**”).

(2) **PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

In light of the Proposed Cancellation of Treasury Shares and Reduction in Registered Capital, and in conjunction with the Company’s operational and development needs, on August 28, 2026, at the second meeting of the sixth session of the Board, the Board proposed to amend the Articles of Association in accordance with the latest revisions to the Company Law of the People’s Republic of China (“**PRC**”), the Securities Law of the PRC and the Guidelines on the Articles of Association of Listed Companies as follows:

Original Articles	Revised Articles
Article 6 The registered capital of the Company is RMB861,026,050.	Article 6 The registered capital of the Company is RMB 855,142,270 .
Article 23 The Company was approved by the CSRC on July 3, 2012 to conduct initial public offering of 13.40 million RMB ordinary shares (hereinafter referred to as the “A Shares”).	Article 23 The Company was approved by the CSRC on July 3, 2012 to conduct initial public offering of 13.40 million RMB ordinary shares (hereinafter referred to as the “A Shares”).

Original Articles	Revised Articles
The number of shares issued by the Company is 861.026050 million, all being ordinary shares, including 737,901,250 shares held by shareholders of domestic listed domestic shares (A Shares), accounting for about 85.70% of the total share capital of the Company; 123,124,800 shares held by overseas listed foreign shares (H Shares) shareholders, accounting for approximately 14.30% of the total share capital of the Company.	The number of shares issued by the Company is 855.142270 million, all being ordinary shares, including 732,017,470 shares held by shareholders of domestic listed domestic shares (A Shares), accounting for about 85.60% of the total share capital of the Company; 123,124,800 shares held by overseas listed foreign shares (H Shares) shareholders, accounting for approximately 14.40% of the total share capital of the Company.
Article 126 The board of directors shall comprise 7 directors and shall have one chairman, 1 vice chairman, 3 independent directors and 1 staff representative director. At least one of the independent directors must possess appropriate accounting or related financial management expertise.	Article 126 The board of directors shall comprise 7 directors and shall have one chairman, 3 independent directors and 1 staff representative director. At least one of the independent directors must possess appropriate accounting or related financial management expertise.
Article 163 The Company shall have one general manager and two co-presidents who shall be appointed or dismissed by the board of directors. The Company shall have several vice general managers, who shall be appointed or removed by the board of directors.	Article 163 The Company shall have one general manager and one co-president who shall be appointed or dismissed by the board of directors. The Company shall have several vice general managers, who shall be appointed or removed by the board of directors.

Save for the proposed amendments to the Articles of Association, other provisions of the Articles of Association shall remain unchanged. The proposed amendments to the Articles of Association were originally prepared in Chinese. In the event of discrepancies between the Chinese and English versions, the Chinese version shall prevail.

The proposed amendments to the Articles of Association are subject to the approval of the Shareholders by way of a special resolution at the EGM. The Board has further resolved to request at the EGM to authorize the Board to delegate the management of the Company to handle the relevant regulatory agency approvals and filing procedures involved in the amendment of the Articles of Association, and to make adjustments to the wordings of such amendments according to opinions of the regulatory authorities.

(3) GENERAL

A circular containing, among other things, details of the (i) Proposed Cancellation of Treasury Shares and Reduction in Registered Capital; and (ii) proposed amendments to the Articles of Association; and (iii) notices convening the EGM and the Class Meetings will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.tigermedgrp.com) and will be provided to the Shareholders who have indicated their wishes to receive a printed copy in due course.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, August 28, 2026

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; and the independent non-executive directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay.